Casein Kinase 2 Signaling in White Matter Stroke

Hung Nguyen, Wenbin Zhu, Selva BaltanFrontiers in Molecular Biosciences 2022 · DOI

Abstract

White matter (WM) injury and axonal dysfunction are primary drivers of long-term disability following a stroke. Recent research identifies Casein Kinase 2 (CK2) as a "master regulator" of this damage. During ischemia, CK2 activates the Cdk5 and AKT/GSK3β signaling pathways, leading to oligodendrocyte death and axonal structural failure. Inhibiting CK2 with the FDA-approved small molecule Silmitasertib (CX-4945) preserves mitochondria and axonal integrity across age groups, even when administered post-ischemia. Furthermore, CK2 inhibition modulates microRNA (miRNA) expression, suggesting an epigenetic component to its neuroprotective effects. Repurposing Silmitasertib represents a promising clinical path for stroke recovery.

The Challenge of White Matter Injury

Stroke research has traditionally focused on gray matter (neuronal cell bodies), but white matter—the axonal "cables" and their insulating myelin—is equally critical for functional recovery. WM injury mechanisms are distinct from gray matter and change significantly with age, making many traditional neuroprotective strategies ineffective in older populations. Current treatments primarily focus on restoring blood flow (reperfusion) but do not address the toxic biochemical cascades that continue to damage the brain after the event. There is a critical need for therapies that protect axons and glia across age groups and remain effective when administered in the hours following a stroke.

CK2: The Master Regulator of Ischemic Damage

CK2 is an unconventional kinase because it is "constitutively active" (always on). However, during a stroke, its localization shifts, and it begins hyper-activating damaging downstream pathways. In white matter, CK2 mediates injury by triggering Cdk5 and AKT/GSK3β signaling.

Schematic of CK2 signaling pathways in white matter during ischemia.

As illustrated in the schematic, ischemia-induced CK2 activation impacts both axons and oligodendrocytes. In axons, it disrupts mitochondrial dynamics and transport, leading to structural injury. In oligodendrocytes, it triggers a Cdk5-mediated cascade resulting in cell death. A key finding is that CK2 inhibition protects mitochondria within axons; since mitochondrial failure is a universal driver of cell death in both young and old tissue, targeting CK2 provides a broad, age-independent protective effect.

Therapeutic Potential and Post-Ischemic Window

Unlike many experimental drugs that only work if given before an injury, CK2 inhibition remains effective when applied after the ischemic insult. This is likely because it specifically regulates the AKT/GSK3β pathway, which remains active during the sub-acute phase of a stroke. In ex vivo models, treatment with CX-4945 (Silmitasertib) led to improved recording of action potentials and significant preservation of complex axonal mitochondrial structures.

Epigenetic Regulation via miRNAs

Beyond direct protein signaling, CK2 inhibition influences the epigenetic landscape by regulating microRNAs (miRNAs). Comparative analyses using NanoString nCounter profiling reveal that ischemia significantly alters the miRNA landscape in white matter, and CK2 inhibition can reverse or modulate these changes.

Differential miRNA expression in white matter following ischemia and CK2 inhibition.

As shown in the data table, CK2 inhibition with CX-4945 differentially regulates several miRNAs, such as miR-501-3p and miR-1959. These miRNAs are known to influence AMPA receptor expression and mitochondrial health, suggesting that miRNA regulation is a primary mechanism through which CK2 inhibitors exert their protective actions against ischemic injury.

Clinical Translation and Future Directions

Silmitasertib (CX-4945) is already FDA-approved and currently in clinical trials for cancer and COVID-19. This existing safety profile significantly lowers the barrier for repurposing the drug for stroke patients. Future research must address sex differences in CK2 signaling, as stroke outcomes often differ between males and females, and further validate the specific cellular targets of the identified miRNAs to facilitate human clinical trials.

Summary updated

Abstract

The growth of the aging population, together with improved stroke care, has resulted in an increase in stroke survivors and a rise in recurrent events. Axonal injury and white matter (WM) dysfunction are responsible for much of the disability observed after stroke. The mechanisms of WM injury are distinct compared to gray matter and change with age. Therefore, an ideal stroke therapeutic must restore neuronal and axonal function when applied before or after a stroke, and it must also protect across age groups. Casein kinase 2 (CK2), is expressed in the brain, including WM, and is regulated during the development and numerous disease conditions such as cancer and ischemia. CK2 activation in WM mediates ischemic injury by activating the Cdk5 and AKT/GSK3β signaling pathways. Consequently, CK2 inhibition using the small molecule inhibitor CX-4945 (Silmitasertib) correlates with preservation of oligodendrocytes, conservation of axon structure, and axonal mitochondria, leading to improved functional recovery. Remarkably, CK2 inhibition promotes WM function when applied after ischemic injury by specifically regulating the AKT/GSK3β pathways. The blockade of the active conformation of AKT confers post-ischemic protection to young and old WM by preserving mitochondria, implying AKT as a common therapeutic target across age groups. Using a NanoString nCounter miRNA expression profiling, comparative analyses of ischemic WM with or without CX-4945 treatment reveal that miRNAs are expressed at high levels in WM after ischemia, and CX-4945 differentially regulates some of these miRNAs. Therefore, we propose that miRNA regulation may be one of the protective actions of CX-4945 against WM ischemic injury. Silmitasertib is FDA approved and currently in use for cancer and Covid patients; therefore, it is plausible to repurpose CK2 inhibitors for stroke patients.
BibTeX
@inproceedings{nguyen2022casein,
  author = {Hung Nguyen and Wenbin Zhu and Selva Baltan},
  title = {{Casein Kinase 2 Signaling in White Matter Stroke}},
  booktitle = {Frontiers in Molecular Biosciences},
  year = {2022},
  doi = {10.3389/fmolb.2022.908521},
}
Figure